Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets

6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Both oncogenic and tumor suppressor functions have been described for junction plakoglobin (JUP), also known as γ-catenin. To clarify the role of JUP in prostate cancer, JUP protein expression was immunohistochemically detected in a tissue microarray containing 11 267 individual prostatectomy specimens. Considering all patients, high JUP expression was associated with adverse tumor stage (P = 0.0002), high Gleason grade (P < 0.0001), and lymph node metastases (P = 0.011). These associations were driven mainly by the subset without TMPRSS2:ERG fusion, in which high JUP expression was an independent predictor of poor prognosis (multivariate analyses, P = 0.0054) and early biochemical recurrence (P = 0.0003). High JUP expression was further linked to strong androgen receptor expression (P < 0.0001), high cell proliferation, and PTEN and FOXP1 deletion (P < 0.0001). In the ERG-negative subset, high JUP expression was additionally linked to MAP3K7 (P = 0.0007) and CHD1 deletion (P = 0.0021). Contrasting the overall prognostic effect of JUP, low JUP expression indicated poor prognosis in the fraction of CHD1-deleted patients (P = 0.039). In this subset, the association of high JUP and high cell proliferation was specifically absent. In conclusion, the controversial biological roles of JUP are reflected by antagonistic prognostic effects in distinct prostate cancer patient subsets.

References Powered by Scopus

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

66858Citations
N/AReaders
Get full text

Wnt signaling in cancer

1963Citations
N/AReaders
Get full text

Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis

1914Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Insights into Circulating Tumor Cell Clusters: A Barometer for Treatment Effects and Prognosis for Prostate Cancer Patients

9Citations
N/AReaders
Get full text

Hsa-miR-133a-3p, miR-1-3p, GOLPH3 and JUP combination results in a good biomarker to distinguish between prostate cancer and non-prostate cancer patients

5Citations
N/AReaders
Get full text

Biomarkers Found in the Tumor Interstitial Fluid may Help Explain the Differential Behavior Among Keratinocyte Carcinomas

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Spethmann, T., Böckelmann, L. C., Labitzky, V., Ahlers, A. K., Schröder-Schwarz, J., Bonk, S., … Lange, T. (2021). Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 15(7), 1956–1969. https://doi.org/10.1002/1878-0261.12922

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

67%

Researcher 1

33%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 2

50%

Agricultural and Biological Sciences 1

25%

Medicine and Dentistry 1

25%

Save time finding and organizing research with Mendeley

Sign up for free